Besides Wall Street's top-and-bottom-line estimates for Veeva (VEEV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2026.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Veeva Systems has underperformed the broader market amid softer demand and competition, while analysts remain moderately optimistic about its future prospects.

The latest trading day saw Veeva Systems (VEEV) settling at $242.75, representing a +1.85% change from its previous close.

Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 2.9% in the morning session after sentiment improved as Wall Street analysts raised their price targets while maintaining positive ratings.

The space company is popular right now, but these other corporations look more attractive.

On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for “agentic commercial,” Veeva’s AI-driven commercial framework designed to modernize field engagement and speed medicine delivery. While Veeva serves as the tech engine driving efficiency in life […]

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems (VEEV) reached $241.51 at the closing of the latest trading day, reflecting a +2.08% change compared to its last close.

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -42.86% and +9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Broker Signals On Veeva Systems Stock A fresh wave of brokerage opinions on Veeva Systems (VEEV) has put the stock back in focus for investors, as firms update their views using earnings estimate revisions and quantitative rating models. These ratings and the underlying Zacks Rank approach do not guarantee any outcome for Veeva Systems investors. They do, however, give you a structured way to compare fresh earnings expectations with the company’s recent share price moves. See our latest...

Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $217.8, denoting a +2.01% move from the preceding trading day.

Privia Health (PRVA) delivered earnings and revenue surprises of -12.50% and +8.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Fundsmith, an investment management firm based in London, has released its second-quarter 2026 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The Fund returned -2.9% in the first half of 2026, underperforming the MSCI World Index by 14.1 percentage points, driven by challenges from a momentum-driven market […]